Patents
Literature
5 results about "Cangrelor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cangrelor (trade name Kengreal in the US and Kengrexal in Europe) is a P2Y₁₂ inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y₁₂ inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. Unlike clopidogrel (Plavix), which is a prodrug, cangrelor is an active drug not requiring metabolic conversion.
Use of clopidogrel or combinations thereof to treat amyotrophic lateral sclerosis, damages caused by the normal aging process, nerve injuries, muscular dystrophy, strenuous physical activities and other conditions that affect synapses as well as skeletal muscles
PendingUS20250281466A1Organic active ingredientsNervous disorderMuscular dystrophyAmyotrophic lateral sclerosis
New treatments using Clopidogrel, Ticagrelor, Prasugrel, and / or Cangrelor and new uses for Clopidogrel are disclosed herein. For example, it has been found that conditions such as ALS (Amyotrophic Lateral Sclerosis), Alzheimer's Disease, the normal aging process, nerve damages, nerve injuries, muscular dystrophy, strenuous physical activities, fatigue, and other conditions that affect synapses as well as skeletal muscles can be treated using Clopidogrel or pharmaceutically acceptable other forms. New mechanisms and modes of action are explained herein.
Owner:BROWN UNIVERSITY
Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
ActiveUS12502400B2Organic active ingredientsPharmaceutical delivery mechanismPediatric patientThrombus
The present invention is directed to the use of cangrelor for the treatment and / or prevention of shunt thrombosis in patients suffering congenital heart diseases undergoing shunt surgery. The invention is also directed to the use of cangrelor for the treatment and / or prevention of stent thrombosis in pediatric patients undergoing stent implantation.
Owner:CHIESI FARMACEUTICI SPA
Preparation and application of double-membrane independently-wrapped nano drug delivery system for regulating immunity
PendingCN120771127AOrganic active ingredientsPharmaceutical non-active ingredientsDiseaseImmunologic disorders
The invention discloses a double-membrane independently wrapped nano drug delivery system for regulating macrophages and platelets. The nano drug delivery system comprises macrophage membrane coated nanoparticles and platelet membrane coated nanoparticles, the macrophage membrane coated nanoparticles are used for adjusting macrophage immune response and loaded with a Toll-like receptor 7 (TLR7) inhibitor, the platelet membrane coated nanoparticles are used for inhibiting abnormal activation of platelets and loaded with a G protein coupled receptor P2Y12 inhibitor, the TLR7 inhibitor comprises at least one of TJ-M2010-5, hydroxychloroquine, Enpatron and IMO-8400, and the TLR7 inhibitor comprises at least one of TJ-M2010-5, hydroxychloroquine, Enpatron and IMO-8400. The P2Y12 inhibitor is prepared from at least one of ticagrelor, clopidogrel, prasugrel and cangrelor. According to the double-membrane independently-wrapped nano drug delivery system, drugs are efficiently delivered to related damaged cells of an inflammation part by utilizing related cell tropism of two cell membranes, immune disorder caused by macrophage and platelet abnormality is inhibited, diseases induced by immune imbalance are treated, an immune microenvironment is regulated and controlled, and the drug delivery effect is improved. And a new direction is provided for treatment of immune diseases.
Owner:SICHUAN UNIV
Pharmaceutical formulations containing high-purity cangrelor and methods for the manufacture and use thereof
Owner:CHIESI FARMACEUTICI SPA
